Which has higher earnings and valuation, VOR or ALMS?

Vor Biopharma has higher earnings, but lower revenue than Alumis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Alumis $24.05M 128.02 -$243.32M -$1.98 N/A

Is VOR or ALMS more profitable?

Vor Biopharma has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Vor Biopharma's return on equity of 0.00% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Alumis -2,825.70% -88.79% -70.72%

Does the media prefer VOR or ALMS?

In the previous week, Vor Biopharma had 1 more articles in the media than Alumis. MarketBeat recorded 4 mentions for Vor Biopharma and 3 mentions for Alumis. Vor Biopharma's average media sentiment score of 0.71 beat Alumis' score of 0.63 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, VOR or GPCR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A

Is VOR or GPCR more profitable?

Vor Biopharma's return on equity of 0.00% beat Structure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Structure Therapeutics N/A -24.91% -23.67%

Does the media refer more to VOR or GPCR?

In the previous week, Structure Therapeutics had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 6 mentions for Structure Therapeutics and 4 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.71 beat Structure Therapeutics' score of 0.28 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ARQT or VOR?

Vor Biopharma has lower revenue, but higher earnings than Arcutis Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arcutis Biotherapeutics $376.07M 8.11 -$16.14M -$0.03 N/A Vor Biopharma N/A N/A N/A N/A N/A

Does the media favor ARQT or VOR?

In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Vor Biopharma. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 4 mentions for Vor Biopharma. Arcutis Biotherapeutics' average media sentiment score of 1.17 beat Vor Biopharma's score of 0.71 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, VOR or DYN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A

Is VOR or DYN more profitable?

Vor Biopharma's return on equity of 0.00% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Dyne Therapeutics N/A -58.28% -46.77%

Does the media prefer VOR or DYN?

In the previous week, Dyne Therapeutics had 6 more articles in the media than Vor Biopharma. MarketBeat recorded 10 mentions for Dyne Therapeutics and 4 mentions for Vor Biopharma. Dyne Therapeutics' average media sentiment score of 1.21 beat Vor Biopharma's score of 0.71 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, RCUS or VOR?

Vor Biopharma has lower revenue, but higher earnings than Arcus Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arcus Biosciences $247M 12.14 -$353M -$3.18 N/A Vor Biopharma N/A N/A N/A N/A N/A

Does the media favor RCUS or VOR?

In the previous week, Arcus Biosciences had 4 more articles in the media than Vor Biopharma. MarketBeat recorded 8 mentions for Arcus Biosciences and 4 mentions for Vor Biopharma. Arcus Biosciences' average media sentiment score of 0.75 beat Vor Biopharma's score of 0.71 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vor Biopharma (VOR) Competitors

$14.36 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$14.36 0.00 (-0.03%)

As of 06/12/2026 07:56 PM Eastern

Compare

VOR vs. ALMS, GPCR, ARQT, DYN, and RCUS

Should you buy Vor Biopharma stock or one of its competitors? MarketBeat compares Vor Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vor Biopharma include Alumis (ALMS), Structure Therapeutics (GPCR), Arcutis Biotherapeutics (ARQT), Dyne Therapeutics (DYN), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.

How does Vor Biopharma compare to Alumis?

Vor Biopharma (NASDAQ:VOR) and Alumis (NASDAQ:ALMS) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

97.3% of Vor Biopharma shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by company insiders. Comparatively, 33.7% of Alumis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Vor Biopharma has higher earnings, but lower revenue than Alumis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Alumis	$24.05M	128.02	-$243.32M	-$1.98	N/A

Vor Biopharma has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Vor Biopharma's return on equity of 0.00% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Alumis	-2,825.70%	-88.79%	-70.72%

Vor Biopharma presently has a consensus target price of $42.25, suggesting a potential upside of 194.22%. Alumis has a consensus target price of $40.30, suggesting a potential upside of 66.87%. Given Vor Biopharma's higher possible upside, equities research analysts plainly believe Vor Biopharma is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Vor Biopharma has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market. Comparatively, Alumis has a beta of -0.55, suggesting that its share price is 155% less volatile than the broader market.

In the previous week, Vor Biopharma had 1 more articles in the media than Alumis. MarketBeat recorded 4 mentions for Vor Biopharma and 3 mentions for Alumis. Vor Biopharma's average media sentiment score of 0.71 beat Alumis' score of 0.63 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vor Biopharma beats Alumis on 9 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Structure Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Structure Therapeutics (NASDAQ:GPCR) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

In the previous week, Structure Therapeutics had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 6 mentions for Structure Therapeutics and 4 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.71 beat Structure Therapeutics' score of 0.28 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Vor Biopharma's return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Structure Therapeutics	N/A	-24.91%	-23.67%

Vor Biopharma has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.35, meaning that its share price is 235% less volatile than the broader market.

Vor Biopharma presently has a consensus target price of $42.25, suggesting a potential upside of 194.22%. Structure Therapeutics has a consensus target price of $106.75, suggesting a potential upside of 148.66%. Given Vor Biopharma's higher probable upside, research analysts clearly believe Vor Biopharma is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

Vor Biopharma beats Structure Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Vor Biopharma compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Vor Biopharma (NASDAQ:VOR) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Arcutis Biotherapeutics currently has a consensus target price of $34.00, indicating a potential upside of 39.46%. Vor Biopharma has a consensus target price of $42.25, indicating a potential upside of 194.22%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Vor Biopharma has lower revenue, but higher earnings than Arcutis Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.11	-$16.14M	-$0.03	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Vor Biopharma. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 4 mentions for Vor Biopharma. Arcutis Biotherapeutics' average media sentiment score of 1.17 beat Vor Biopharma's score of 0.71 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.3% of Vor Biopharma shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 0.3% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Arcutis Biotherapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market.

Vor Biopharma has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Vor Biopharma's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Vor Biopharma	N/A	N/A	N/A

Summary

Vor Biopharma beats Arcutis Biotherapeutics on 9 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Dyne Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Dyne Therapeutics (NASDAQ:DYN) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Vor Biopharma's return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Dyne Therapeutics	N/A	-58.28%	-46.77%

In the previous week, Dyne Therapeutics had 6 more articles in the media than Vor Biopharma. MarketBeat recorded 10 mentions for Dyne Therapeutics and 4 mentions for Vor Biopharma. Dyne Therapeutics' average media sentiment score of 1.21 beat Vor Biopharma's score of 0.71 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vor Biopharma presently has a consensus price target of $42.25, suggesting a potential upside of 194.22%. Dyne Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 92.41%. Given Vor Biopharma's higher possible upside, equities research analysts clearly believe Vor Biopharma is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94

Vor Biopharma has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Summary

Dyne Therapeutics beats Vor Biopharma on 6 of the 11 factors compared between the two stocks.

How does Vor Biopharma compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Vor Biopharma (NASDAQ:VOR) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Vor Biopharma has lower revenue, but higher earnings than Arcus Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.14	-$353M	-$3.18	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Arcus Biosciences has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market.

Arcus Biosciences presently has a consensus price target of $35.10, suggesting a potential upside of 47.17%. Vor Biopharma has a consensus price target of $42.25, suggesting a potential upside of 194.22%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 0.3% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Vor Biopharma has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Vor Biopharma's return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Vor Biopharma	N/A	N/A	N/A

In the previous week, Arcus Biosciences had 4 more articles in the media than Vor Biopharma. MarketBeat recorded 8 mentions for Arcus Biosciences and 4 mentions for Vor Biopharma. Arcus Biosciences' average media sentiment score of 0.75 beat Vor Biopharma's score of 0.71 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vor Biopharma beats Arcus Biosciences on 8 of the 13 factors compared between the two stocks.

Get Vor Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VOR vs. The Competition

Export

Metric	Vor Biopharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$778.17M	$407.67M	$4.29B	$12.05B
Dividend Yield	N/A	N/A	10.25%	5.66%
P/E Ratio	N/A	N/A	22.29	24.42
Price / Sales	N/A	320.73	159.50	110.81
Price / Cash	N/A	N/A	40.19	37.92
Price / Book	N/A	2.49	26.92	6.82
Net Income	N/A	-$81.71M	$116.61M	$337.56M
7 Day Performance	8.05%	-0.93%	0.25%	1.16%
1 Month Performance	-1.85%	-12.31%	0.25%	3.16%
1 Year Performance	N/A	N/A	14.24%	30.60%

Vor Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VOR Vor Biopharma	2.4352 of 5 stars	$14.36 flat	$42.25 +194.2%	N/A	$778.17M	N/A	N/A	140
ALMS Alumis	3.0393 of 5 stars	$24.15 +15.6%	$40.30 +66.9%	+669.1%	$3.08B	$24.05M	N/A	N/A	High Trading Volume
GPCR Structure Therapeutics	2.9643 of 5 stars	$42.93 -0.9%	$106.75 +148.7%	+98.0%	$3.05B	N/A	N/A	136
ARQT Arcutis Biotherapeutics	4.1506 of 5 stars	$24.38 -0.9%	$34.00 +39.5%	+81.5%	$3.05B	$376.07M	N/A	150	Positive News
DYN Dyne Therapeutics	3.0638 of 5 stars	$18.19 +1.3%	$35.00 +92.4%	+26.2%	$3.01B	N/A	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VOR) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vor Biopharma (VOR) Competitors

VOR vs. ALMS, GPCR, ARQT, DYN, and RCUS

How does Vor Biopharma compare to Alumis?

Summary

How does Vor Biopharma compare to Structure Therapeutics?

Summary

How does Vor Biopharma compare to Arcutis Biotherapeutics?

Summary

How does Vor Biopharma compare to Dyne Therapeutics?

Summary

How does Vor Biopharma compare to Arcus Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vor Biopharma (VOR) Competitors

VOR vs. ALMS, GPCR, ARQT, DYN, and RCUS

How does Vor Biopharma compare to Alumis?

Do insiders and institutionals believe in VOR or ALMS?

Which has higher earnings and valuation, VOR or ALMS?

Is VOR or ALMS more profitable?

Do analysts recommend VOR or ALMS?

Which has more volatility and risk, VOR or ALMS?

Does the media prefer VOR or ALMS?

Summary

How does Vor Biopharma compare to Structure Therapeutics?

Does the media refer more to VOR or GPCR?

Which has preferable earnings and valuation, VOR or GPCR?

Do institutionals and insiders believe in VOR or GPCR?

Is VOR or GPCR more profitable?

Which has more volatility and risk, VOR or GPCR?

Do analysts rate VOR or GPCR?

Summary

How does Vor Biopharma compare to Arcutis Biotherapeutics?

Do analysts prefer ARQT or VOR?

Which has higher earnings and valuation, ARQT or VOR?

Does the media favor ARQT or VOR?

Do insiders & institutionals believe in ARQT or VOR?

Which has more risk & volatility, ARQT or VOR?

Is ARQT or VOR more profitable?

Summary

How does Vor Biopharma compare to Dyne Therapeutics?

Is VOR or DYN more profitable?

Does the media prefer VOR or DYN?

Do institutionals & insiders believe in VOR or DYN?

Do analysts recommend VOR or DYN?

Which has more volatility & risk, VOR or DYN?

Which has stronger earnings and valuation, VOR or DYN?

Summary

How does Vor Biopharma compare to Arcus Biosciences?

Which has preferable valuation and earnings, RCUS or VOR?

Which has more risk & volatility, RCUS or VOR?

Do analysts recommend RCUS or VOR?

Do institutionals & insiders hold more shares of RCUS or VOR?

Is RCUS or VOR more profitable?

Does the media favor RCUS or VOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools